28 results about "Aneurysm dissecting" patented technology

The application provides a multifunctional nano particle for targeting abdominal aortic aneurysm and a preparation method and application thereof, and belongs to the field of nanobiomedicine, wherein polyphenol oxidation self-polymer nanoparticles are used as carriers, doxycycline is loaded, and a targeting ligand cRGD is modified on the surface of the nano carrier; the neovasculature in the media and adventitia of AAA sites helps accumulation of the nanoparticles in the abdominal aortic aneurysm, and the integrin αν3 beta receptor highly expressed on the surface of the diseased cell membrane can recognize the cRGD with high affinity, and then mediate the targeted endocytosis of the nanoparticles; after intravenous injection, the nanoparticles can be effectively enriched in the lesion site and achieve long-term retention, and can release DC in response to the high ROS level in the tumor microenvironment; the drug is rapidly released to take effect, and the non-specific toxic side effects are reduced; the free radical scavenging capacity of the nanoparticles can be synergized with the DC activity to treat AAA through multiple mechanisms such as anti-inflammatory, antioxidant, macrophage repolarization promotion, anti-apoptosis and calcification inhibition, and MMPs inhibition.

The invention belongs to the technical field of biology, and particularly relates to a tremella aurantialba methanol extract and a preparation method and application thereof.The preparation method comprises the following steps that S1, pretreatment is conducted, specifically, a prepared tremella aurantialba raw material is freeze-dried, and the dried raw material is ground; s2, extraction: adding an extraction solvent methanol-water solution, and performing magnetic stirring for extraction; s3, post-treatment: after the extraction is completed, combining the extracting solutions, filtering, performing vacuum concentration to obtain paste, and performing vacuum freeze-drying on the obtained paste to obtain the tremella aurantialba methanol extract. The tremella aurantialba methanol extract can obviously relieve the occurrence and progress of Ang II induced aneurysm, not only provides a new medicine for preventing and treating abdominal aortic aneurysm, but also provides a new thought for development and utilization of tremella aurantialba resources.

The invention discloses gamma-aminobutyric acid and application of a pharmaceutical composition thereof in preparation of drugs for preventing or treating aortic dissection and aortic aneurysm. The invention provides the application of gamma-aminobutyric acid in preparation of drugs for preventing or treating aortic dissection for the first time, and verifies the application of gamma-aminobutyric acid in preparation of drugs for preventing and / or treating aortic dissection and aortic aneurysm by inhibiting endothelial cell dysfunction; the application of gamma-aminobutyric acid in preparation of drugs for preventing and / or treating aortic dissection and aortic aneurysm by inhibiting expression of c-FOS to reduce vascular endothelial cell injury is verified; the application of gamma-aminobutyric acid in preparation of drugs for preventing and / or treating aortic dissection and aortic aneurysm by reducing infiltration of macrophages is verified.

The invention provides lipid nanoparticles taking zinc phosphate as an inner core, a preparation method of the lipid nanoparticles and a medicine for treating aortic aneurysm, and relates to the technical field of biological medicines. The lipid nanoparticles provided by the invention comprise zinc phosphate nanoparticles, DOPA (Dioctyl-Phthalate Polyamide), ionizable cationic lipid, cholesterol and PEG (Polyethylene Glycol) lipid, the zinc phosphate nano-particles are inner cores of the lipid nano-particles. The lipid nanoparticles have excellent biocompatibility and safety and stable structure, and can improve the stability and delivery efficiency of nucleic acid (such as FBN1mRNA) as a carrier, thereby realizing effective treatment of diseases. According to the medicine for treating the aortic aneurysm, provided by the invention, accurate delivery of FBN1mRNA and expression in FBN1 cells can be realized, and angiogenesis and repair are promoted, so that accurate treatment of the aortic aneurysm is realized.

The invention discloses an abdominal aortic aneurysm serum protein fingerprint detection and analysis method and system based on an LASSO regression algorithm. The method comprises the following steps: by optimizing a serum sample pretreatment process and combining an MALDI-TOFMS (Matrix-Assisted Laser Desorption / Ionization Time of Flight Mass Spectrometry) mass spectrometry technology and high-throughput proteomics data analysis, screening differentially expressed proteins related to occurrence, development and rupture of abdominal aortic aneurysm in serum; and further constructing a risk assessment model based on the key protein combination by using an LASSO machine learning algorithm. The method provided by the invention has the advantages of high sensitivity and good specificity, can effectively distinguish abdominal aortic aneurysm patients from normal people, can accurately predict the rupture risk of abdominal aortic aneurysm, especially early small aneurysm, and provides important tools and bases for clinical early diagnosis, risk stratification and personalized treatment decision.

The invention relates to the technical field of animal model construction, and discloses a mouse abdominal aortic aneurysm model construction method. The construction method comprises the step that in a 18-month-old mouse, a sterile cotton piece soaked with elastinase is used for wrapping the kidney subabdominal aorta to induce formation of the abdominal aortic aneurysm. The mouse model can better reflect the degenerative change of the aortic wall of an elderly patient, better fits the clinical manifestation in the development speed and severity of aortic aneurysm, can more stably simulate the development process of the abdominal aortic aneurysm of the elderly patient, can be used as an effective tool for studying senescence-related aneurysm diseases, and has a wide application prospect. The method is helpful for revealing acceleration and aggravation processes of the elderly individuals in pathological development, and provides a more targeted theoretical basis and experimental support for designing and evaluating a new treatment method.

The present invention relates to an internal duct and fixing system (100) for branches for endovascular endoprostheses for endovascular treatment of aneurysms or dissections of the aorta, comprising (i) an endoprosthesis (200) provided with windows (210, 220, 230, 240), (ii) one or more occlusions (215, 225, 235, 245), fixed to the endoprosthesis (200) by means of suture (216, 226, 236, 246), reversibly occluding the windows (210, 220, 230, 240), and a set of fixing and duct elements (300) that forms one or more internal channels of the endoprosthesis (200), preferably in the region adjacent to one of the windows (210, 220, 230, 240). The present invention also relates to a corresponding endoprosthesis (200).

The invention belongs to the technical field of biology, and particularly relates to application of a medicine for inhibiting eEF2 in aortic dissection and aneurysm medicine and application of NFATc3 serving as an aortic dissection and aneurysm medicine target. The invention provides an application of NFATc3 as an aortic dissection and aneurysm drug target. The relationship between the NFATc3 and the aortic dissection and the aneurysm is found for the first time, specifically, the expression of the NFATc3 in the VSMCs of the human aortic aneurysm is obviously up-regulated, and the expression of the NFATc3 of cytoplasm and cell nucleus is obviously increased in human and mouse AAD tissues. Based on the discovery, the invention provides a new application of a targeted NFATc3 drug in preparation of drugs for preventing or / and treating aortic dissection and aneurysm. Experiments show that the development of aortic dissection and aneurysm can be significantly slowed down by inhibiting the expression or function of NFATc3.

The invention discloses an aortic aneurysm or aortic dissection filling piece and component, the filling piece is made of polyurethane shape memory foam, the expansion rate of the polyurethane shape memory foam is larger than 100 times, and a preparation method of the polyurethane shape memory foam comprises the steps that 1, the filling piece is made of polyurethane shape memory foam, and the expansion rate of the polyurethane shape memory foam is larger than 100 times; the preparation method comprises the following steps: preparing a polyurethane acrylate prepolymer from macromolecular polyol, diisocyanate, a chain extender containing disulfide bonds, other micromolecular chain extenders and an acrylate end-capping reagent; and 2, uniformly mixing the polyurethane acrylate prepolymer, a foaming agent, a foaming promoter, a photoinitiator and a high-boiling-point solvent to obtain a foaming solution, and sequentially carrying out light curing and foaming on the foaming solution to obtain the polyurethane shape memory foam. The filling piece is made of polyurethane shape memory foam and fully expands to form thrombus to fill a tumor cavity, and meanwhile, the filling piece is made of degradable materials and can be subsequently absorbed by the tumor cavity, so that foreign matter is prevented from being left in the body for a long time.

The present invention relates to an internal duct and fixing system (100) for branches for endovascular endoprostheses for endovascular treatment of aneurysms or dissections of the aorta, comprising (i) an endoprosthesis (200) provided with windows (210, 220, 230, 240), (ii) one or more occlusions (215, 225, 235, 245), fixed to the endoprosthesis (200) by means of suture (216, 226, 236, 246), reversibly occluding the windows (210, 220, 230, 240), and a set of fixing and duct elements (300) that forms one or more internal channels of the endoprosthesis (200), preferably in the region adjacent to one of the windows (210, 220, 230, 240). The present invention also relates to a corresponding endoprosthesis (200).

An axially compressible bare stent for an aorta, formed by interleaving at least two wires having different diameters, i.e., a first wire and a second wire, in an overlapping manner. In a natural release state, the bare stent has a metal coverage of at least 30%. The first wire has a diameter of 20-150 μm, and the second wire has a diameter of 150-600 μm. During the use in the treatment of aortic aneurysms and / or aortic dissection lesions, low liquid permeability and a strong radial support force are provided at a desired location in an aorta by means of the axial compressibility of the bare stent.

Various concepts relate to Iliac branch endoprostheses extending for a length between a proximal end and a distal end, the iliac bifurcated endoprosthesis bifurcated from a primary flow channel into two flow channels. Various concepts relate to methods of deploying an endoprosthesis system to treat an aortic aneurysm including deploying an iliac bifurcated endoprosthesis into an ipsilateral leg of a bifurcated main body endoprosthesis, or a contralateral gate of a bifurcated main body endoprosthesis.

The invention discloses application of KAT7 as a target spot in treatment of aortic aneurysm and dissection. According to the application, an AngII-induced aortic aneurysm mouse model is applied, the treatment effect of the KAT7 inhibitor WM3835 on aortic aneurysm / dissection is detected through mouse survival rate, aortic aneurysm occurrence rate, aorta width, blood vessel staining and WB staining indexes, and the WM3835 can slow down the occurrence and progress of aortic aneurysm, reduce the occurrence of aortic dissection and improve the survival rate of aortic aneurysm / dissection, so that the KAT7 inhibitor WM3835 can be used for treating aortic aneurysm / dissection. And a new target and a new medicine are provided for clinically treating aorta and dissection of aortic aneurysm. The KAT7 inhibitor WM3835 provided by the invention is a brand new drug treatment means for treating aortic aneurysm and dissection, is an important supplement for operative treatment of aortic aneurysm / dissection, and has important clinical significance.

The invention provides application of a lactic dehydrogenase inhibitor in preparation of a medicine for preventing and / or treating aneurysm. The lactic dehydrogenase inhibitor is selected from a compound shown as a formula I in the specification or pharmaceutically acceptable salt thereof. Experiments show that the lactic dehydrogenase inhibitor can specifically inhibit synthesis of lactic acid in thoracic aortic aneurysm, recover expression of systolic genes, significantly inhibit vascular inflammation, maintain the systolic state of vascular smooth muscle cells and delay progress of thoracic aortic aneurysm. In addition, the lactic dehydrogenase inhibitor can also show a remarkable effect of inhibiting vasodilatation in thoracic aortic aneurysm mice, and has no remarkable influence on normal C57BL / 6J mice, so that the lactic dehydrogenase inhibitor is proved to have targeting and specific effects on thoracic aortic aneurysm. The lactic dehydrogenase inhibitor can also significantly inhibit vascular wall inflammatory response and elastic fiber destruction and delay the progress of thoracic aortic aneurysm by recovering the steady state function of vascular smooth muscle cells.

Various concepts involve an iliac bifurcation prosthesis extending a length between the proximal and distal ends, which bifurcates from the main flow channel into two flow channels. Various concepts also involve methods for deploying an in-situ prosthesis system to treat aortic aneurysms, including deploying the iliac bifurcation prosthesis into the ipsilateral leg of the bifurcation main prosthesis or into the contralateral opening of the bifurcation main prosthesis.

The invention relates to the field of animal models, in particular to sgRNA for preparing an aortic aneurysm animal model and a preparation method, and the sgRNA is characterized in that a TB structural domain of an exon 57 part of an FBN1 gene is knocked out on Bama miniature pig cells through a CRISPR / Cas9 gene editing method. The important structural domain of the FBN1 gene and the TB structural domain of the exon 57 part are screened out by deeply analyzing the structure and the function of the FBN1 gene and combining bioinformatics prediction and disease model related research. The prepared Bama miniature pig subjected to specific gene editing is expected to show unique value in medical research, disease model construction or specific animal husbandry production application, and powerful support is provided for research and development of related fields.

The invention belongs to the technical field of biological medicines, and particularly provides application of prasugrel or pharmaceutically acceptable salts thereof in preparation of medicines for preventing and / or treating aortic aneurysm. The prasugrel or the pharmaceutically acceptable salt thereof is independently used or is combined with other medicines for preventing and / or treating aortic aneurysm. The activity of GLUD1 is enhanced through leucine, so that conversion of Glu to alpha-KG is promoted, degradation of Glu is promoted, namely, the Glu level is reduced by enhancing degradation of Glu, and aortic aneurysm is improved. In a Glu metabolic network, Gln can be converted into Glu under the action of glutaminase 1 (GLS1), so that the generation of Glu is inhibited by inhibiting the activity of GLS1, and the effect of preventing and / or treating aortic aneurysm is achieved.

The present invention discloses a kit for predicting the growth and rupture risk of aortic aneurysms based on protein lactylation levels. The present invention constructs an aortic aneurysm and dissection mouse model, detects the protein lactylation level in its vascular tissue, and divides it into a high lactate level group and a low lactate level group. It is found that the formation of aortic aneurysms and the occurrence of aortic dissection are reduced in mice with low lactate levels. Further survival analysis shows that the survival curves between the two groups are significantly different. Therefore, on the basis of aortic aneurysm detection indicators, with protein lactylation level as the entry point, by identifying protein lactylation level, the protein lactylation level is associated with the growth and rupture risk of aortic aneurysms, thereby achieving the purpose of early prediction of aortic aneurysm deterioration and dissection occurrence, which is helpful for the prediction and early diagnosis and treatment of clinical critical events, and reduces the occurrence of serious adverse events such as dissection.

A stent graft for surgical delivery in a target site of a patient to treat an aortic aneurysm. The stent graft includes a graft formed of graft material including a first portion to be received by a lower portion of an aorta that is relatively straight, and a second portion to be received by an upper portion of an aorta that is curved. The stent graft includes a stent attached to the graft including stent members. In a first orientation, the first and second portions of the graft material are folded between the stent members over first and second adjacent portions of the graft to form a first pleat and a second pleat. In a second orientation, the second pleat has a graft space between corresponding stent members on a greater curvature side of the stent graft that is greater than on a lesser curvature side of the stent graft.

The present invention relates to a novel method for preventing or treating an aneurysm by using an IGF1R inhibitor and use. The present invention also relates to a formulation comprising IGF1C suitable for the method and use. The present invention further relates to a local minimally invasive delivery technique of drugs for preventing or treating an aneurysm, and in particular, to a local minimally invasive delivery technique for delivering a medicament comprising an IGF1R inhibitor according to the present invention.

The application relates to the technical field of biological medicine, and discloses an engineered exosome, a preparation method and purposes thereof. The method comprises the following steps: introducing an exogenous nucleic acid coding a human TIMP3 protein into endothelial progenitor cells to construct engineered cells, and obtaining exosomes by separating and purifying the supernatant after culture. The engineered exosome is secreted by the endothelial progenitor cells and is efficiently loaded with the TIMP3, and has both cell homing characteristics and protease inhibition functions. The exosome can significantly inhibit matrix metalloproteinase 3 (MMP3) activity, reduce extracellular matrix degradation, and improve the structural stability of a blood vessel wall. The application provides a novel and efficient cell-free delivery strategy for treating aortic dissection, aneurysm and other vascular remodeling diseases.

The invention discloses a mononuclear cell knapsack delivery system of targeted aortic dissection tissue as well as a preparation method and application of the mononuclear cell knapsack delivery system. A'mononuclear cell knapsack type delivery system 'is constructed, a drug is firstly wrapped in tiny vesicles or nanoparticles (NPs) and is non-covalently adhered to the surfaces of mononuclear cells through a reversible metal-polyphenol network formed by ferric ions, tannic acid and the like, and after intravascular administration, the mononuclear cells reach interlayer lesion tissues along with blood flow, so that the mononuclear cells can be quickly delivered to the surface of the mononuclear cells. The drug is migrated and enriched by chemotaxis of focus inflammatory factors, cell factors and the like, and the drug is released in a focus microenvironment, so that the purposes of actively targeting aortic dissection tissues and effectively treating aortic aneurysm and dissection are achieved. The mononuclear cell knapsack-type targeted delivery system provided by the invention does not destroy biological functions of mononuclear cells, can stably load nano-drugs and realize effective drug release in an interlayer or an interlayer early-stage lesion tissue, and shows a good clinical application prospect.

The invention discloses a Phocaecola vulgaris bacterium and an application of a metabolite tetrahydrofolic acid of the Phocaecola vulgaris bacterium in treatment of abdominal aortic aneurysm. According to the application disclosed by the invention, the fact that the abundance of the Phocaecola vulgaris and the metabolite is in negative correlation with the progress of the aneurysm is proved for the first time, and an animal model verifies that the expansion of the angiotensin-induced abdominal aortic aneurysm of a mouse can be obviously inhibited by oral administration of the Phocaecola vulgaris or intraperitoneal injection of tetrahydrofolic acid, so that the survival rate is increased, and an innovative strategy is provided for the treatment of the abdominal aortic aneurysm.

Various concepts relate to Iliac branch endoprostheses extending for a length between a proximal end and a distal end, the iliac bifurcated endoprosthesis bifurcated from a primary flow channel into two flow channels. Various concepts relate to methods of deploying an endoprosthesis system to treat an aortic aneurysm including deploying an iliac bifurcated endoprosthesis into an ipsilateral leg of a bifurcated main body endoprosthesis, or a contralateral gate of a bifurcated main body endoprosthesis.

The invention discloses application of salidroside in preparation of a medicine for inhibiting thoracic aortic dissection aneurysm. The invention provides application of salidroside in preparation of a product with any one of the following functions: 1) preventing thoracic aortic dissection aneurysm; 2) the occurrence or progress of thoracic aortic dissection aneurysm is slowed down or inhibited; 3) the occurrence rate of thoracic aortic dissection aneurysm is reduced; and 4) protecting the aorta. The invention finds that the salidroside can significantly improve the occurrence and progress of the thoracic aortic dissection aneurysm of mice, provides a new application approach of the salidroside, and provides a new drug choice for treating the thoracic aortic dissection aneurysm.

The invention relates to a novel method for preventing or treating aneurysm by using an IGF1R (Insulin-like Growth Factor 1 Receptor) inhibitor and application. The invention also relates to formulations comprising IGF1C suitable for use in this method and use. The invention also relates to a local minimally invasive delivery technique of a drug for preventing or treating aneurysm, in particular to a local minimally invasive delivery technique for delivering a drug comprising an IGF1R inhibitor of the invention.

A pharmaceutical composition for preventing an aortic aneurysm is provided including a medium chain fatty acid as a main component, which has an effect of inhibiting the occurrence and progression of the aortic aneurysm. Thus, when the aortic aneurysm is found, the composition through continuous intake can exhibit effects including inhibition of the progression of the aortic aneurysm and improvement in the vital prognosis.

The application discloses a kind of abdominal aortic aneurysm serum protein fingerprint detection analysis method and system based on LASSO regression algorithm.The method is by optimizing serum sample pretreatment process, in combination with MALDI-TOFMS mass spectrometry technology and high-throughput proteomics data analysis, screening the differential expression protein in serum related to abdominal aortic aneurysm occurrence, development and rupture;Further utilize LASSO machine learning algorithm to construct risk assessment model based on key protein combination.The method of the application has the advantages of high sensitivity, good specificity, can effectively distinguish abdominal aortic aneurysm patients and normal population, and can accurately predict the rupture risk of abdominal aortic aneurysm, especially early small aneurysm, provide important tool and basis for clinical early diagnosis, risk stratification and personalized treatment decision.